Tags

Type your tag names separated by a space and hit enter

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
Pediatrics. 2007 Jan; 119(1):11-8.Ped

Abstract

BACKGROUND

Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants worldwide. Previous studies of a live pentavalent human-bovine reassortant rotavirus vaccine have shown it to be efficacious across a range of potencies.

OBJECTIVE

Our goal was to evaluate the efficacy, immunogenicity, and safety of pentavalent rotavirus vaccine at the end of shelf life in healthy infants.

PATIENTS AND METHODS

During 2002-2004, 1312 healthy infants approximately 6 to 12 weeks old from the United States (47%) and Finland (53%) were randomly assigned to receive 3 oral doses of vaccine (vaccine at approximately 1.1 x 10(7) infectious U per dose) or placebo approximately 4 to 10 weeks apart. Infants were to be followed for acute gastroenteritis through 1 rotavirus season after vaccination and for adverse events postvaccination.

RESULTS

Three doses of pentavalent rotavirus vaccine at the end of shelf life demonstrated efficacy against rotavirus gastroenteritis caused by human G-serotypes included in the vaccine (G1-G4). Efficacy against severe rotavirus gastroenteritis was 100%, and efficacy against any rotavirus gastroenteritis regardless of severity was 72.5%. A threefold rise in G1 serum neutralizing was observed in 57% and in anti-rotavirus immunoglobulin A in 96% of pentavalent rotavirus vaccine recipients. No statistically significant increase in vomiting, diarrhea, or irritability was observed among pentavalent rotavirus vaccine recipients compared with placebo recipients within the 7-day period from each dose. A statistically significant increase in fevers (> or = 100.5 degrees F, rectal equivalent) was observed among pentavalent rotavirus vaccine recipients compared with placebo recipients after dose 1.

CONCLUSIONS

This pentavalent human-bovine rotavirus vaccine was generally well tolerated, efficacious, and immunogenic at the end of shelf life.

Authors+Show Affiliations

Kentucky Pediatric/Adult Research, Bardstown, Kentucky, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

17200266

Citation

Block, Stan L., et al. "Efficacy, Immunogenicity, and Safety of a Pentavalent Human-bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life." Pediatrics, vol. 119, no. 1, 2007, pp. 11-8.
Block SL, Vesikari T, Goveia MG, et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11-8.
Block, S. L., Vesikari, T., Goveia, M. G., Rivers, S. B., Adeyi, B. A., Dallas, M. J., Bauder, J., Boslego, J. W., & Heaton, P. M. (2007). Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics, 119(1), 11-8.
Block SL, et al. Efficacy, Immunogenicity, and Safety of a Pentavalent Human-bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life. Pediatrics. 2007;119(1):11-8. PubMed PMID: 17200266.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. AU - Block,Stan L, AU - Vesikari,Timo, AU - Goveia,Michelle G, AU - Rivers,Stephen B, AU - Adeyi,Ben A, AU - Dallas,Michael J, AU - Bauder,Jeffrey, AU - Boslego,John W, AU - Heaton,Penny M, AU - ,, PY - 2007/1/4/pubmed PY - 2007/1/31/medline PY - 2007/1/4/entrez SP - 11 EP - 8 JF - Pediatrics JO - Pediatrics VL - 119 IS - 1 N2 - BACKGROUND: Rotavirus is the leading cause of dehydrating acute gastroenteritis in infants worldwide. Previous studies of a live pentavalent human-bovine reassortant rotavirus vaccine have shown it to be efficacious across a range of potencies. OBJECTIVE: Our goal was to evaluate the efficacy, immunogenicity, and safety of pentavalent rotavirus vaccine at the end of shelf life in healthy infants. PATIENTS AND METHODS: During 2002-2004, 1312 healthy infants approximately 6 to 12 weeks old from the United States (47%) and Finland (53%) were randomly assigned to receive 3 oral doses of vaccine (vaccine at approximately 1.1 x 10(7) infectious U per dose) or placebo approximately 4 to 10 weeks apart. Infants were to be followed for acute gastroenteritis through 1 rotavirus season after vaccination and for adverse events postvaccination. RESULTS: Three doses of pentavalent rotavirus vaccine at the end of shelf life demonstrated efficacy against rotavirus gastroenteritis caused by human G-serotypes included in the vaccine (G1-G4). Efficacy against severe rotavirus gastroenteritis was 100%, and efficacy against any rotavirus gastroenteritis regardless of severity was 72.5%. A threefold rise in G1 serum neutralizing was observed in 57% and in anti-rotavirus immunoglobulin A in 96% of pentavalent rotavirus vaccine recipients. No statistically significant increase in vomiting, diarrhea, or irritability was observed among pentavalent rotavirus vaccine recipients compared with placebo recipients within the 7-day period from each dose. A statistically significant increase in fevers (> or = 100.5 degrees F, rectal equivalent) was observed among pentavalent rotavirus vaccine recipients compared with placebo recipients after dose 1. CONCLUSIONS: This pentavalent human-bovine rotavirus vaccine was generally well tolerated, efficacious, and immunogenic at the end of shelf life. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/17200266/Efficacy_immunogenicity_and_safety_of_a_pentavalent_human_bovine__WC3__reassortant_rotavirus_vaccine_at_the_end_of_shelf_life_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=17200266 DB - PRIME DP - Unbound Medicine ER -